174 related articles for article (PubMed ID: 22863202)
1. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.
Gerspacher M; Fairhurst RA; Mah R; Roehn-Carnemolla E; Furet P; Fritsch C; Guthy DA
Bioorg Med Chem Lett; 2015 Sep; 25(17):3582-4. PubMed ID: 26164189
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
4. Selective and potent small-molecule inhibitors of PI3Ks.
Jeong Y; Kwon D; Hong S
Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
[TBL] [Abstract][Full Text] [Related]
6. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Fairhurst RA; Gerspacher M; Imbach-Weese P; Mah R; Caravatti G; Furet P; Fritsch C; Schnell C; Blanz J; Blasco F; Desrayaud S; Guthy DA; Knapp M; Arz D; Wirth J; Roehn-Carnemolla E; Luu VH
Bioorg Med Chem Lett; 2015 Sep; 25(17):3575-81. PubMed ID: 26199119
[TBL] [Abstract][Full Text] [Related]
7. Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Fairhurst RA; Imbach-Weese P; Gerspacher M; Caravatti G; Furet P; Zoller T; Fritsch C; Haasen D; Trappe J; Guthy DA; Arz D; Wirth J
Bioorg Med Chem Lett; 2015 Sep; 25(17):3569-74. PubMed ID: 26206504
[TBL] [Abstract][Full Text] [Related]
8. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
9. PI3 kinase inhibitors in the clinic: an update.
Kurtz JE; Ray-Coquard I
Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
[TBL] [Abstract][Full Text] [Related]
10. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
[TBL] [Abstract][Full Text] [Related]
11. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
Safina BS; Sweeney ZK; Li J; Chan BK; Bisconte A; Carrera D; Castanedo G; Flagella M; Heald R; Lewis C; Murray JM; Nonomiya J; Pang J; Price S; Reif K; Salphati L; Seward EM; Wei B; Sutherlin DP
Bioorg Med Chem Lett; 2013 Sep; 23(17):4953-9. PubMed ID: 23867164
[TBL] [Abstract][Full Text] [Related]
12. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
13. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
14. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
[TBL] [Abstract][Full Text] [Related]
15. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
[TBL] [Abstract][Full Text] [Related]
16. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
17. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
Murray JM; Sweeney ZK; Chan BK; Balazs M; Bradley E; Castanedo G; Chabot C; Chantry D; Flagella M; Goldstein DM; Kondru R; Lesnick J; Li J; Lucas MC; Nonomiya J; Pang J; Price S; Salphati L; Safina B; Savy PP; Seward EM; Ultsch M; Sutherlin DP
J Med Chem; 2012 Sep; 55(17):7686-95. PubMed ID: 22877085
[TBL] [Abstract][Full Text] [Related]
18. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
19. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
[TBL] [Abstract][Full Text] [Related]
20. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]